Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Street Poller Media and The Boom of the Street Interview Ad Industry 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Toyota Global Sales Fall as China Demand Slumps 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Amazon Secures 200 MW Wind Power Deals in Sweden 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Add as a preferred source on Google
MALVERN, Pa., April 05, 2018 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that it has completed dosing in the first cohort of subjects in its Phase 1 clinical trial of PB2452 (formerly MEDI2452), a reversal agent for the antiplatelet therapy ticagrelor.
The randomized, double-blind, placebo-controlled, single ascending dose trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous PB2452 with and without ticagrelor pre-treatment in up to nine cohorts and a total of approximately 60 healthy volunteers.
“PB2452 has the potential to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations, like urgent surgery or severe bleeding, providing a unique differentiator among oral P2Y12 antagonist antiplatelet agents,” said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio. “In preclinical studies, PB2452 demonstrated high affinity and specific binding to ticagrelor, and was shown to reverse ticagrelor-mediated inhibition of platelet aggregation and to normalize bleeding.i PhaseBio in-licensed PB2452 from MedImmune in November 2017, and we are thrilled with its rapid progression into clinical trials.”
About PB2452
PB2452 (formerly MEDI2452) is a neutralizing Fab antibody fragment that binds to ticagrelor and its active metabolite AR-C124910XX, and is intended to reverse the antiplatelet effects of ticagrelor. The availability of PB2452 would enable reversal of the antiplatelet effects of ticagrelor in rare emergency situations and greatly reduce the waiting period before surgery.
About PhaseBio
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases. PhaseBio is leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. The company is also developing PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
[email protected]
i Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood. 2015; 125(22): 3484-3490. doi:10.1182/blood-2015-01-622928.
